X

Trial Profile

A Cancer Research UK (CR-UK) Phase I Trial of LY3143921 a Cdc7 Inhibitor in Adult Patients with Advanced Solid Tumours

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LY-3143921 (Primary)
Indications Advanced breast cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Adverse reactions; First in man

Most Recent Events

17 Oct 2023 Planned End Date changed from 31 Jul 2023 to 28 Feb 2027.
17 Oct 2023 Planned primary completion date changed from 31 Jul 2023 to 28 Feb 2027.
26 Jul 2022 Planned End Date changed from 6 Nov 2020 to 31 Jul 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com